循环瘤DNA反应的决定因素和复发/反射性地幔细胞淋巴瘤的结果
Leo Meriranta1, Rasmus Rask Kragh Jørgensen2, Annika Pasanen3
1University of Helsinki, Helsinki University Hospital Comprehensive Cancer Centre and iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland.
Blood advances
|May 22, 2025
概括
这项研究揭示了循环瘤DNA (ctDNA) 可以预测复发性/耐药性地幔细胞淋巴瘤 (R/R MCL) 的治疗反应. ctDNA分析提供了新的最小侵入性工具,以指导R/R MCL临床决策.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 现有有限的临床工具用于指导复发性和耐火性地幔细胞淋巴瘤 (R/R MCL) 的治疗.
- 在R/R MCL中循环瘤DNA (ctDNA) 的临床实用性在很大程度上尚未得到证实.
研究的目的:
- 用ctDNA研究R/R MCL患者治疗反应和治疗结果的分子决定因素.
- 评估ctDNA作为指导R/R MCL临床决策的最小侵入性工具.
主要方法:
- 基于面板的ctDNA双重测序应用于58名R/R MCL患者,这些患者接受了venetoclax,lenalidomide和rituximab治疗.
- 分析包括基因分析,ctDNA度,对最小残留疾病的动态ctDNA评估,以及对克隆性血液形成 (CH) 的评估.
主要成果:
- SMARCA4突变预测了反应,而TP53突变表明了对治疗的抗性.
- 治疗前ctDNA度与疾病特征和存活率相关,独立于分子预测因素.
- 动态ctDNA评估确定了PCR遗漏的折射性,碎片化特征区分了MCLctDNA和CH-cfDNA.
结论:
- 在MCL中的新型ctDNA特征为R/R MCL的临床决策提供了最少侵入性的工具.
- ctDNA分析可以补充临床评估并揭示治疗折射性.
- 了解CH对于管理毒性和预测R/RMCL的结果很重要.
更多相关视频
08:04In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
11.6K
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
相关概念视频
02:40Cancer Stem Cells and Tumor Maintenance
4.7K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.7K
02:56Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K